Efeitos da administração aguda de topiramato sobre o comportamento de camundongos em campo aberto
DOI:
https://doi.org/10.34024/rnc.2011.v19.8403Palavras-chave:
Camundongo, Atividade Locomotora, Topiramato, ComportamentoResumo
Embora o topiramato (TPM) seja utilizado para tratar doenças em humanos, poucos são os estudos de seus efeitos sobre o comportamento em modelos animais. Objetivo. Este estudo teve como objetivo avaliar o efeito da administração aguda de TPM sobre o comportamento de ratos submetidos ao teste de campo aberto. Método. Os animais foram divididos em dois grupos: o grupo tratamento (n = 10), que recebeu 10 mg/kg intraperitoneal de TPM e o grupo controle (n = 10), que recebeu solução salina. Após 30 minutos de administração da droga, os animais foram avaliados durante 5 minutos no teste de campo aberto. Os seguintes parâmetros foram analisados: número de quadrados explorados, tempo de imobilidade, tempo de permanência na área central, tempo de permanência na área periférica, tempo de permanência em pé, frequência e tempo de grooming, tempo em pé durante o último minuto, número de bolos fecais e a velocidade estimada. Resultados. O grupo tratamento teve um maior número de locais explorados (p = 0.02) e maior velocidade estimada (p = 0.01). Conclusão. Os resultados sugerem que a administração aguda de TPM aumenta a atividade locomotora de camundongos sem interferir com a aprendizagem, ansiedade, estresse e comportamento exploratório.
Referências
Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35:241-56. DOI: https://doi.org/10.1006/phrs.1997.0124
Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 1995;36:S105-14. DOI: https://doi.org/10.1111/j.1528-1157.1995.tb05993.x
Vieta E, Gilabert A, Rodriguez A, Garcia-Castrillon A, Luna MJ, Arrufat E, et al. Effectiveness and safety of topiramate in treatment-resistant bipolar disorder. Actas Esp Psiquiatr 2001;29:148-52.
Maidment ID. The use of topiramate in mood stabilization. Ann Pharmacother 2002;36:1277-81. DOI: https://doi.org/10.1345/aph.1A398
Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 2003; 19:59-68. DOI: https://doi.org/10.1097/00002508-200301000-00008
Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003;26:1-4. DOI: https://doi.org/10.1097/00002826-200301000-00001
McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep 2003;7:135-8. DOI: https://doi.org/10.1007/s11916-003-0023-3
Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother 2004;4:751-8. DOI: https://doi.org/10.1586/14737175.4.5.751
Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004; 12:167S-73S. DOI: https://doi.org/10.1038/oby.2004.284
Choi JW, Kim WK. Is topiramate a potential therapeutic agent for cerebral hypoxic/ischemic injury? Exp Neurol 2007;203:5-7. DOI: https://doi.org/10.1016/j.expneurol.2006.09.014
Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, et al. The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilep Behav 2007;10:486-94. DOI: https://doi.org/10.1016/j.yebeh.2007.02.007
Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973;21:205-35. DOI: https://doi.org/10.1016/S0003-3472(73)80065-X
Walsh RN, Cummins RA. The Open-Field Test: a critical review. Psychol Bull 83 1976;83:482-504. DOI: https://doi.org/10.1037/0033-2909.83.3.482
Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003;463:3-33. DOI: https://doi.org/10.1016/S0014-2999(03)01272-X
Pedrazza EL, Riboldi GP, Pereira GS, Izquierdo I, Bonan CD. Habituation to an open field alters ecto-nucleotidase activities in rat hippocampal synaptosomes. Neurosci Lett 2007;413:21-4. DOI: https://doi.org/10.1016/j.neulet.2006.11.023
Izquierdo I, Izquierdo LA, Barros DM, Souza TM, Souza MM, Quevedo J, et al. Differential involvement of cortical receptor mechanisms in working, short-term and long-term memory. Behav Pharmacol 1998;9:421-7. DOI: https://doi.org/10.1097/00008877-199809000-00005
Tang V, Warden J, Cullen N, Rutledge E. Topiramate in traumatic brain injury: adverse effects on cognitive function. J Head Trauma Rehabil 2007;22:409-10. DOI: https://doi.org/10.1097/01.HTR.0000300236.21114.bc
Choleris E, Thomas AW, Kavaliers M, Prato FS. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci Biobehav Rev 2001;21:235-60. DOI: https://doi.org/10.1016/S0149-7634(01)00011-2
Alaverdashvili M, Kubova H, Mares P. Motor performance and behavior of immature rats are not compromised by a high dose of topiramate. Epilepsy Behav 2005;7:222-30. DOI: https://doi.org/10.1016/j.yebeh.2005.04.013
Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401. DOI: https://doi.org/10.1126/science.283.5400.397
Jones SR, Gainetdinov RR, Caron MG. Application of microdialysis and voltammetry to assess dopamine functions in genetically altered mice: correlation with locomotor activity. Psychopharmacology (Berl) 1999; 147:30-2. DOI: https://doi.org/10.1007/s002130051137
Adriani W, Felici A, Sargolini F, Roullet P, Usiello A, Oliverio A, et al. N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res 1998;123:52 9. DOI: https://doi.org/10.1007/s002210050544
Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004;29:1465-79. DOI: https://doi.org/10.1016/j.addbeh.2004.06.014
Eltayb A, Wadenberg ML, Schilstrom B, Svensson TH. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol 2005;372:195-202. DOI: https://doi.org/10.1007/s00210-005-0014-5
Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003;26:199-206. DOI: https://doi.org/10.1097/00002826-200307000-00010
Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24:290-4. DOI: https://doi.org/10.1097/00002826-200109000-00006
Smith C. Drug Interactions between Psychoactive Agents and Antiepileptic Agents. Epilepsy Behav 2001;2:92-105. DOI: https://doi.org/10.1006/ebeh.2001.0165
Alvarez Jdo N, Fukushiro DF, Tatsu JA, Carvalho EP, Gandolfi AC, Tsuchiya JB, et al. Amphetamine-induced rapid-onset sensitization: role of novelty, conditioning and behavioral parameters. Pharmacol Biochem Behav 2006;83:500-7. DOI: https://doi.org/10.1016/j.pbb.2006.03.010
